Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQB3912 in advanced malignancies
NCT05997342Phase 1Completed
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Aug 2023
- Primary completion
- May 2025
- Modality
- Reversible Covalent Inhibitors, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of tqb3912 in Advanced Malignant Solid Neoplasm (AMSN), sponsored by Chia Tai-Tianqing Pharmaceutical Group. Primary endpoints: Dose Limiting Toxicities at 28 days, Maximum Tolerated Dose at 29 days and 1 more. Started Aug 2023; status: completed.
02
Drugs
tqb3912
03
Conditions
Advanced Malignant Solid Neoplasm (AMSN)
Beyond the preview
Go deeper on NCT05997342.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05997342.